Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WYETH CORDARONE WILL BE $150 MIL. DRUG "SHORTLY", AHP SAYS; NEW CLINICAL TRIAL DATA WILL SUPPORT APPLICATION FOR PREVENTION OF ARRHYTHMIC DEATH INDICATION

Executive Summary

Wyeth-Ayerst's anti-arrhythmic Cordarone is "going to go over the $150 mil. mark very shortly," American Home Products Exec VP Fred Hassan reported at AHP's R&D day in Pearl River, N.Y. March 28.

You may also be interested in...



Orudis KT sales of $28.7 mil. recorded in first two months on the market -- AHP data.

ORUDIS KT SALES OF $28.7 MIL. IN FIRST TWO MONTHS on the market are reported by American Home Products in recent sales data for 1995. The new Rx-to-OTC switch analgesic began retail shipments on Nov. 8 and was expected to be widely available by November 17 ("The Tan Sheet" Nov. 20, p. 3).

Orudis KT sales of $28.7 mil. recorded in first two months on the market -- AHP data.

ORUDIS KT SALES OF $28.7 MIL. IN FIRST TWO MONTHS on the market are reported by American Home Products in recent sales data for 1995. The new Rx-to-OTC switch analgesic began retail shipments on Nov. 8 and was expected to be widely available by November 17 ("The Tan Sheet" Nov. 20, p. 3).

ELAN, ALZA DELIVER STRONG GAINS IN FIRST QUARTER AS FIRMS ENHANCE DRUG DEVELOPMENT EFFORTS; NOVARTIS MERGER SPAWNS RUMORS OF STILL MORE Rx DEALS

Elan's diversification from drug delivery into drug discovery has won the company an enthusiastic following on Wall Street. The stock posted a 32% gain for the first quarter, closing at 64-1/4.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel